Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

According to Scotiabank, Syfovre's market launch may encounter challenges due to potential unfavorable gross-to-net adjustments. Despite the revenue and EPS misses, not all indicators were negative ...

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company ... and hematopoietic stem cell ...

Izervay and Syfovre are addressing a potentially enormous ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

While Syfovre targets complement C3 ... Funding for the acquisition will come from a combination of cash, loans and a commercial paper instrument, according to Astellas, which estimates that ...